AR124316A1 - Compuestos para tratar una enfermedad respiratoria - Google Patents

Compuestos para tratar una enfermedad respiratoria

Info

Publication number
AR124316A1
AR124316A1 ARP210103448A ARP210103448A AR124316A1 AR 124316 A1 AR124316 A1 AR 124316A1 AR P210103448 A ARP210103448 A AR P210103448A AR P210103448 A ARP210103448 A AR P210103448A AR 124316 A1 AR124316 A1 AR 124316A1
Authority
AR
Argentina
Prior art keywords
compounds
conditions
treat
respiratory disease
diseases
Prior art date
Application number
ARP210103448A
Other languages
English (en)
Inventor
Stephen Collingwood
Jonathan David Hargrave
Duncan Alexander Hay
Clive Mcarthy
Thomas Beauregard Schofield
Edward Walker
Naomi Went
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of AR124316A1 publication Critical patent/AR124316A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula general (1) en donde R¹, R², R³, R⁴, R⁵, Y y Z son como se define en la presente, son útiles para el tratamiento de enfermedades respiratorias y otras enfermedades y afecciones moduladas por TMEM16A. Reivindicación 32: Un método de acuerdo con la reivindicación 31, en donde las enfermedades y afecciones afectadas por la modulación de TMEM16A se seleccionan de enfermedades y afecciones respiratorias, boca seca (xerostomía), hipermovilidad intestinal, colestasis y afecciones oculares.
ARP210103448A 2020-12-11 2021-12-10 Compuestos para tratar una enfermedad respiratoria AR124316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063124395P 2020-12-11 2020-12-11

Publications (1)

Publication Number Publication Date
AR124316A1 true AR124316A1 (es) 2023-03-15

Family

ID=80448601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103448A AR124316A1 (es) 2020-12-11 2021-12-10 Compuestos para tratar una enfermedad respiratoria

Country Status (7)

Country Link
US (1) US20240132467A1 (es)
EP (1) EP4259607A1 (es)
JP (1) JP2023552638A (es)
CN (1) CN116745267A (es)
AR (1) AR124316A1 (es)
TW (1) TW202237090A (es)
WO (1) WO2022123314A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
SI1986633T1 (sl) * 2006-02-10 2015-03-31 Summit Corporation Plc Zdravljenje Duchennove mišične distrofije
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PT2488486T (pt) * 2009-10-13 2019-11-05 Ligand Pharm Inc Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos
KR101194995B1 (ko) * 2009-10-14 2012-10-29 주식회사 이큐스앤자루 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
US20140243324A1 (en) * 2010-11-18 2014-08-28 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CA3111392A1 (en) * 2018-09-04 2020-03-12 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
AU2020290049A1 (en) * 2019-06-12 2022-02-03 Tmem16A Limited Compounds for treating respiratory disease
JP7335963B2 (ja) * 2019-08-29 2023-08-30 富士フイルム株式会社 感活性光線性又は感放射線性樹脂組成物、感活性光線性又は感放射線性膜、パターン形成方法、及び電子デバイスの製造方法

Also Published As

Publication number Publication date
CN116745267A (zh) 2023-09-12
JP2023552638A (ja) 2023-12-18
WO2022123314A1 (en) 2022-06-16
EP4259607A1 (en) 2023-10-18
TW202237090A (zh) 2022-10-01
US20240132467A1 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
EA202190006A1 (ru) Пуриноновые соединения и их применение при лечении рака
DE602004019198D1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
RU2007133709A (ru) Производные в-циклодекстрина в качестве антибактериальных агентов
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
PA8477001A1 (es) Inhibidores no peptidilicos de la union a las celulas dependientes de la vla-4 utiles en el tratamiento de enfermedades inflamatorias autoinmunes y respiratorias
UY39261A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
AR008676A1 (es) Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen
SG162753A1 (en) Methods of treating cancer and other conditions or disease states using lfmau and ldt
BR112022023025A2 (pt) Moduladores de htt para tratar doença de huntington
CL2021000515A1 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
WO2021243291A3 (en) Oligonucleotides for sars-cov-2 modulation
CL2023001301A1 (es) 1,4-diazepanonas bicíclicas y sus usos terapéuticos.
MA28340A1 (fr) Derives de l'acide 7- amino-4- quinolone-3-carboxylique substitues par un groupe cycloalkyle, methode pour leur production et leur utilisation en tant que medicaments
UY38665A (es) Agentes antiproliferativos para el tratamiento de pah
AR124316A1 (es) Compuestos para tratar una enfermedad respiratoria
BR112021024043A2 (pt) Implante mamário biológico
ECSP045396A (es) Proceso para preparar derivados de 6-alquiliden penem
EP4169925A3 (en) Process to make n-substituted tetrahydrothienopyridine derivatives
CO2022000084A2 (es) Compuestos para tratar enfermedad respiratoria
MX2021000625A (es) Dinucleotidos ciclicos como agonistas de sting.
NI201000065A (es) CARBONO UNIDO A LOS MODULADORES DE LA y-SECRETASA.